PTC Therapeutics -18% after negative opinion on muscular dystrophy drug

• PTC Therapeutics (NASDAQ:PTCT) -18.1% premarket on news that a committee of the European Medicines Agency did not recommend conditional approval for its drug for the treatment of muscular dystrophy.
• PTCT says the decision underscores the importance of its Phase 3 clinical trial, which is on track to complete enrollment in mid-2014 with top-line data expected in mid-2015; PTCT intends to request a re-examination of the opinion with a final outcome expected in Q2 2014.